Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access
US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.
You may also be interested in...
As of Oct. 1, the fee for rare pediatric disease and tropical disease priority review vouchers will be $2.83m; the increase follows a slight decline in FY 2017.
Keeping Track: US FDA's Late Summer Approval Extravaganza Stars Three Novel Agents, Features Return Of Mylotarg
Kymriah, Vabomere, and benzidazole approvals joined by new indications for Austedo, Faslodex.
Original new drugs and biologics recently approved by US FDA.